{ "docId": "019de518-6502-70bc-9a44-c6a9c7f323b5", "docSlug": "4230ce80abe7092521a593effe59cbcd", "documentTitle": "Oculis | Investor Presentation Deck | 48 slides", "authorId": "oculis", "authorName": "Oculis", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-04-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "pageCount": 48, "prevPage": 40, "nextPage": 42, "slideType": "product_demo", "function": "present_solution", "density": "overcrowded", "nDataPoints": 20, "notes": null, "elementsJson": null, "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019de518-6502-70bc-9a44-c6a9c7f323b5/41", "deckHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5", "deckJsonHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5.json", "deckAnchorHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5#slide-41", "components": [ { "bbox": { "h": 0.22, "w": 0.34, "x": 0.038, "y": 0.35 }, "kind": "chart", "text": "Eyedrops RGCs count/20x field % of Efficacy Sham control Glaucoma NGF (200µg/ml) OCS-05 (200µg/ml) OC5-05 (400µg/ml) 36.54 15.73 30.00 29.86 28.19 82.1 81.7 77.1", "attrs": {}, "subkind": "bar-vertical", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "0b29463c-9eea-480f-a205-71baa21229bc", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.22, "w": 0.34, "x": 0.038, "y": 0.605 }, "kind": "chart", "text": "Intravitreal Nt RGCs/20Xfield % of Efficacy Sham control Glaucoma OCS-05 26.7 21.8 25.8 96.3", "attrs": {}, "subkind": "bar-vertical", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "abcf72f2-a76a-4886-a92b-a791434086f6", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.505, "w": 0.299, "x": 0.67, "y": 0.35 }, "kind": "chart", "text": "Clinical assessment (score) Severe disabilities Treatment initiation Placebo OCS-05 50 mpk OCS-05 100 mpk Normal D1 D3 D5 D7 D9 D11 D13 D15 D17 D19 D21 D23 D25 D27 D29 D31 D33 D35 D37 D39 D41 D43 D45 D47", "attrs": {}, "subkind": "line", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "fa56a6e1-cc73-483b-84b0-ba40de38d97e", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.602, "w": 0.229, "x": 0.392, "y": 0.337 }, "kind": "image", "text": "Sham control RGC Loss of RGC Placebo OCS-05 70 mg/kg More RGC remain", "attrs": {}, "subkind": "screenshot", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "b62cba8b-6458-498f-997a-7b861cb41372", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.016, "w": 0.29, "x": 0.689, "y": 0.325 }, "kind": "list", "text": "OCS – 05 | Model of autoimmune AON and MS", "attrs": {}, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "27690684-bb98-4bf9-928b-9bad177dc49a", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.016, "w": 0.206, "x": 0.401, "y": 0.274 }, "kind": "list", "text": "Visual of RGC Protection", "attrs": {}, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "2c94ab86-088c-4e1d-abb3-f3624afa7067", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.016, "w": 0.302, "x": 0.042, "y": 0.309 }, "kind": "list", "text": "OCS – 05 | H&E for RGC density at week 61", "attrs": {}, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "8a01f6f3-ff78-4913-a3da-5e19d27bf5da", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.336, "x": 0.035, "y": 0.84 }, "kind": "paragraph", "text": "High-pressure Glaucoma rat model of neurodegeneration without inflammation", "attrs": {}, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "1e3f5e52-b2ee-4d9d-8a23-b9617a681c62", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.336, "x": 0.035, "y": 0.199 }, "kind": "paragraph", "text": "OCS-05, IVT and topical, shown to prevent RGC damage (the key element in Glaucoma vision loss)", "attrs": {}, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "25a97a70-07c0-4cc5-b50e-3a3b89ab9a01", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.24, "x": 0.392, "y": 0.199 }, "kind": "paragraph", "text": "AON model: Short term study (5-day treatment, assessment at day 6)", "attrs": {}, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "66c6625f-5b56-4348-9cd3-7506882e094b", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.279, "x": 0.684, "y": 0.199 }, "kind": "paragraph", "text": "OCS-05 shown to promote improvement of clinical function (disability) in experimental autoimmune encephalomyelitis (EAE) model", "attrs": {}, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f013aad6-9652-4aa5-8556-db3da951376f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.013, "w": 0.288, "x": 0.675, "y": 0.87 }, "kind": "source-note", "text": "Experimental Autoimmune Encephalomyelitis model in mice", "attrs": { "numbered": true }, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "a20beb61-0be3-49f1-a35a-e6189bab9057", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.049, "w": 0.342, "x": 0.029, "y": 0.917 }, "kind": "source-note", "text": "EAE, experimental autoimmune encephalomyelitis; H&E, hematoxylin and eosin staining; MS, multiple sclerosis; RGC, retinal ganglion cell 1. Villoslada P. et al. Neurotherapeutics. 2019; 16(3):808-827", "attrs": { "numbered": true }, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "a9b44b07-6d28-4da2-b224-808484f0edf6", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.023, "w": 0.86, "x": 0.029, "y": 0.086 }, "kind": "title", "text": "Compelling preclinical data showing prevention of RGC damage in Glaucoma and AON models", "attrs": {}, "subkind": "action-title", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "3714bf68-f27b-4487-8cf0-6a84cc69ef34", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.035, "w": 0.604, "x": 0.029, "y": 0.043 }, "kind": "title", "text": "OCS-05 | Neuro-Ophthalmology Candidate", "attrs": {}, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "42782437-ceb0-4aea-9b4a-999e72b7ba03", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [ { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "agent": "Designer", "layer": "slide", "matchId": "eb82d34a-a997-4899-a14a-cecdd994ae37", "evidence": "chart/line: Clinical assessment (score) Severe disabilities Treatment initiation Placebo OCS-05 50 mpk OCS-05 100 mpk Normal D1 D3 D5 D7 D9 D11 D13 D15 D17 D19 D21 D23 D25 D27 D29 D31 D33 D35 D37 D39 D41 D43 D45 D47", "confidence": 0.7 } ], "frameworks": [], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }